TORNTPHARM stock news on Anadi Algo News

Monday, June 15, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|7 matching stories

TORNTPHARM Share Price, Latest News & Sentiment

Latest AI-analyzed news for TORNTPHARM, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

TORNTPHARM News Today

Large-cap stock hub

The pharma sector often acts as a defensive play, but positive analyst calls can provide short-term trading opportunities. Lower crude prices generally benefit the broader economy, indirectly supporting consumer-facing sectors like media and beverages.

Coverage
7
recent stories
Sources
3
distinct publishers
Bias Split
5 bullish / 1 bearish
1 neutral stories
Window
86d
recent coverage span
Saved Quote Snapshot

TORNTPHARM

Last Updated
23 May 2026
Price
NA
NA
52W Range
NA - NA
exchange snapshot
PE / VWAP
PE NA
VWAP NA
Trend Read
bullish
Bullish stack · EMA 5 > 9 > 21 > 50
Business Context
Industry: NA
Sector Trail: NA
Listing Date: NA
Market Structure
F&O Eligible: No
Indices: NA
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Consolidated results
What This Quarter Says

Torrent Pharmaceuticals has filed its latest quarterly report. We can see their revenue was ₹2809 crore and profit was ₹503 crore. This information is now on record for investors to review.

Revenue
Rs 2,809 cr
up 18.2% vs previous filing
Profit
Rs 503 cr
up 3.7% vs previous filing
EPS / Finance Cost
EPS 14.88
Finance cost Rs 57 cr
Filing Context
Filed 24 Jan 2025, 11:03 pm
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 2,809 cr, up 18.2% vs previous filing.
  • Profit this quarter: Rs 503 cr, up 3.7% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 14.88.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

TORNTPHARM FAQ

Why is TORNTPHARM in the news right now?

TORNTPHARM has appeared across 7 recent stories from 3 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is TORNTPHARM coverage bullish or bearish right now?

TORNTPHARM coverage is currently leaning bullish, with 5 bullish, 1 bearish, and 1 neutral analyzed stories in the recent window.

Which themes are moving with TORNTPHARM?

Recent TORNTPHARM coverage is clustering around Pharmaceuticals and Healthcare. Related names showing up alongside TORNTPHARM include LUPIN, ADANIGAS, ALLIEDBL.

How should I use this TORNTPHARM news page?

Use this page as a coverage hub for TORNTPHARM: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use TORNTPHARM coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
For pharma, look for confirmation of buying interest in TORNTPHARM. For ALLIEDBL and ZEEL, consider short-term long positions with strict stop-losses, given these are analyst-driven calls.|Quick check: ALLIEDBL neutral, TORNTPHARM bullish bias (+3.0% 1d).

Latest TORNTPHARM Stock Coverage

Market has likely priced this in given the article age; however, monitor global crude and gas prices for sustained impact on CGD stocks.
Consider long positions in Indian pharmaceutical companies actively developing or launching generic GLP-1 drugs, as the market opportunity is substantial.
Consider long positions in ZYDUSLIFE and TORNTPHARM on dips, as this collaboration targets a high-growth therapeutic area with significant market potential.